TRANSFORM is a phase II study of the molecule GSK3915393 for slowing the progression and reducing the symptoms of idiopathic pulmonary fibrosis.
You may receive the investigational molecule or a placebo. The treatment is administered orally.
To participate, you must have received a diagnosis of idiopathic pulmonary fibrosis.
Clic here to access the official record from the National Library of Medicine for this study